Amide compound and use thereof as integrin α4β7 antagonist
By developing amide compounds as integrin α4β7 antagonists, the problem of poor efficacy of existing integrin inhibitors in the treatment of inflammatory bowel disease has been solved, and effective inhibition of intestinal inflammation has been achieved.
WO2026138844A1PCT designated stage Publication Date: 2026-07-02HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC
- Filing Date
- 2025-12-24
- Publication Date
- 2026-07-02
AI Technical Summary
Technical Problem
Existing oral integrin inhibitors are not very effective in treating diseases such as inflammatory bowel disease, and there is a need to develop new integrin α4β7 antagonists.
Method used
Amide compounds are provided as integrin α4β7 antagonists. The specific structure consists of compounds of formula (II) and their tautomers, stereoisomers, hydrates, solvates, pharmaceutically acceptable salts or prodrugs, and their efficacy is improved by substitution of specific groups.
Benefits of technology
Amide compounds effectively inhibit integrin α4β7, reduce intestinal inflammation, and have potential therapeutic effects on inflammatory diseases such as Crohn's disease and ulcerative colitis.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN2025144979_02072026_PF_FP_ABST
Abstract
Provided in the present invention are a new compound that effectively antagonizes integrin α4β7, which is a compound as represented by the following formula (II), or a tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug of the compound as represented by the following formula (II).
Need to check novelty before this filing date? Find Prior Art